Immunoregulatory role of IL-38 in rheumatoid arthritis: integrated analysis of pro-inflammatory cytokine interactions, HLA-DRB1 and PTPN22 gene expression, and treatment-related variations
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease characterized by aberrant cytokine signaling and genetic predisposition. Recent evidence has emerged linking Interleukin-38 (IL-38), an IL-1 family member cytokine, to serving as a putative immunomodulatory mediator of inflammation. This study aimed to examine the role of IL-38 in rheumatoid arthritis and correlate it with inflammatory cytokines, clinical disease activity indices and RA susceptibility genes ( HLA-DRB1 and PTPN22 ) expression. A total of 140 subjects, including 70 rheumatoid arthritis (RA) patients and 70 healthy controls (HC), were included. Clinical parameters were gathered (disease duration, DAS28-ESR, ESR, pain score, tender joint count and swollen joint count). Serum levels of IL-38, IL-6, IL-17 A, TNF-α, RF (rheumatoid factor), anti-CCP antibodies and complement C3 and C4 were measured using immunological assays. Expression levels of HLA-DRB1 and PTPN22 were measured using real-time quantitative PCR, by the 2⁻ΔΔCt method, through the use of GAPDH as an internal reference gene. Cytokine levels were correlated with clinical parameters and gene expression. Rheumatoid arthritis patients had increased serum IL-38 levels compared to healthy controls (154.77 ± 36.72 vs. 82.53 ± 6.75 pg/mL; p < 0.001) and these correlated weakly to moderately with indicators of disease activity, such as DAS28-ESR ( r = 0.40, p < 0.001), ESR ( r = 0.27, p = 0.023) and pain score ( r = 0.30, p = 0.013). IL-38 correlated weakly and positively with main inflammatory cytokines, especially IL-17 A ( r = 0.29, p = 0.014) and TNF-α ( r = 0.30, p = 0.012). Subgroup analysis showed significant differences in IL-38 levels among treatment groups ( p < 0.001) with the highest levels in patients treated with methotrexate and lowest levels observed in patients receiving biologic therapy. In rheumatoid arthritis patients, gene expression analysis showed a significant increase of HLA-DRB1 (4.24 ± 1.79 vs. 1.02 ± 0.21; p < 0.001) and decrease in PTPN22 expression (0.51 ± 0.17 vs. 1.01 ± 0.16; p < 0.001). Moreover, levels of IL-38 correlated weakly and positively with HLA-DRB1 expression ( r = 0.28, p = 0.020), whereas a moderate negative correlation was established for PTPN22 expression ( r = − 0.55, p < 0.001). IL-38 is weakly to moderately correlated with inflammatory cytokines, clinical disease activity and RA susceptibility gene expression, with the exception of a moderate inverse association with PTPN22. These results indicate that IL-38 might be a candidate immunological marker linked to inflammatory signaling systems and genetic susceptibility mechanisms in rheumatoid arthritis, warranting further validation in larger, longitudinal cohorts.
Authors
- Ahmed Flayyih Hasan (ORCID: https://orcid.org/0009-0007-9208-5046)
- Hiba Abdulameer Mohammed (ORCID: https://orcid.org/0000-0002-5990-8668)
- Mohanad Salam Hussein (ORCID: https://orcid.org/0009-0009-7714-9245)
- Ahmed M. Amshawee (ORCID: https://orcid.org/0009-0007-5016-5697)
- Yasir Chnani (ORCID: https://orcid.org/0009-0008-9556-471X)
- Mais Nameer Abdul-Samad
- Rafid Abdulwahid Abdulkarrem
Institutions
- University of Baghdad (IQ)
- Mustansiriyah University (IQ)
- University of Babylon (IQ)
- Al-Farabi University (IQ)
- University of Hillah (IQ)
- Nahrain University (IQ)
Publication Details
- Journal
- BMC Rheumatology
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1186/s41927-026-00709-w
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00